Navigation Links
Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer
Date:6/22/2009

SEATTLE, June 22 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the "Company") today announced that Merck KGaA of Darmstadt, Germany, has initiated a global Phase 3 trial of Stimuvax(R) (BLP25 liposome vaccine, L-BLP25) in patients with hormone receptor-positive, locally advanced, recurrent or metastatic breast cancer. Stimuvax is an investigational therapeutic cancer vaccine being developed by Merck KGaA under a license agreement with Oncothyreon.

The Phase 3 trial, named STRIDE (STimulating immune Response In aDvanced brEast cancer), is anticipated to enroll more than 900 patients at approximately 180 sites in over 30 countries - including North America, Europe, Asia and Australia. Patients with estrogen receptor-positive and/or progesterone receptor-positive, non-resectable locally advanced, recurrent or metastatic breast cancer receiving hormonal therapy will be randomized to receive either Stimuvax or a placebo in a 2:1 ratio. The primary endpoint of STRIDE is progression-free survival. Overall survival, quality of life, tumor response and safety will also be assessed in this study.

"Advanced-stage breast cancer remains a devastating and challenging disease and we urgently need new treatment options," said Dr. Larry Shulman, Chief Medical Officer and Senior Vice President for Medical Affairs, Dana-Farber Cancer Institute, Boston, Massachusetts, and Principal Investigator of STRIDE. "If the results from the Phase 3 STRIDE study prove positive, this could make a difference for patients with hormone receptor positive metastatic breast cancer."

"The initiation of the STRIDE study is an enormous step forward in clinical breast cancer research and represents our continued commitment to developing Stimuvax within a robust clinical trial program across several cancer types. We are very excited that Stimuvax will now be test
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncothyreon appoints Scott Peterson as Vice President of Research and Development
2. Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
3. Oncothyreon announces closing of $11.1 million registered direct financing
4. Oncothyreon announces commitments to purchase $11.1 million of company securities in a registered direct financing
5. Oncothyreons PX-866 is effective in preclinical model of pulmonary fibrosis
6. Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
7. Oncothyreon reports first quarter 2009 financial results
8. Oncothyreon regains compliance with NASDAQ listing requirements
9. Oncothyreon to present at Invest Northwest 2009
10. Oncothyreon reports full year and fourth quarter 2008 financial results
11. Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 Freeslate, ... solutions, today announced that Lupin Limited, one of India’s ... CM Protégé PharmD System for high throughput ... India, is focused on a wide range of quality, ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Carahsoft and ... Thursday, January 23, 2014 at 2pm EST (11am PST), ... The topic focuses on how technology can turn raw, ... decisions for government agencies. The online webinar will last ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of strategic ... business, and media events in the United States ... associate Virginia Cox , JD, is returning to the firm,s ... Cox re-joins 3D after more than two years of service ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2
... Ltd. (NYSE Amex:, SVA ), a leading developer and provider of ... and twelve month,periods ended December 31, 2008. , , ... 2008 sales increasing 39% year-over-year to $46.5, ... in 2008, up from 5.12 million in, ...
... Calif., April 9 Jivan announced today ... high-throughput transcriptome sequencing (RNA-Seq) and expression. Leveraging ... mRNA in biological samples, Jivan will provide ... will offer content for targeted sequencing with ...
... expansion of PROVENT(R) Sleep Apnea Therapy in Limited ... Inc. a privately-held, medical device company, focused on ... the appointment of John McCutcheon as President and ... company also announced that current CEO Jeffrey Nugent ...
Cached Biology Technology:Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 2Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 3Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 4Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 5Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 6Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 7Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 8Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 9Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 10Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 11Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 12Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 13Jivan Focuses on Solutions for Transcriptome Sequencing 2Ventus Medical Appoints John McCutcheon as President and CEO 2
(Date:4/17/2014)... fish consumption advisories for expecting mothers are ineffective ... persistent organic pollutants (POPs). , The study, ... of Toronto Scarborough PhD student Matt Binnington and ... of environmental contamination, a mother,s compliance with advisories, ... influenced exposure in her children. , Their model ...
(Date:4/17/2014)... engineer has developed a patented technique that improves ... The same technique could help police during drug ... Kay L. Theede chair in engineering and department ... research team have created a template-based system that ... The distance detection method called stand-off bomb ...
(Date:4/17/2014)... honeybees in Europe, Asia and the United States are ... be impacting native honeybee populations at this time, according ... include including Nosema microsporidia and Varroa ... resilient to these invasive pests, which suggests to us ... Asia and the United States currently are not necessary ...
Breaking Biology News(10 mins):Fish consumption advisories fail to cover all types of contaminants 2Patented research remotely detects nitrogen-rich explosives 2East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3
... Harbor, N.Y. One way of regulating protein levels in ... These are intermediary molecules that are first copied from DNA ... then transported into the cell,s body to be translated into ... Spring Harbor Laboratory (CSHL) has now discovered that mRNAs can ...
... Without aggressive action to reduce soot emissions, the ... to be significantly accelerated in order to achieve international ... last December,s Copenhagen Accord, according to " Assessing the ... published online June 21 in the Proceedings of the ...
... the Danish Cancer Society and the Herlev University Hospital ... for multiple tumor markers in bladder cancer. The ... multiple short synthetic probes: application to methylation analysis of ... from patients with bladder cancer," appears in the July ...
Cached Biology News:Messenger RNAs are regulated in far more ways than previously appreciated, CSHL team finds 2Aggressive action to reduce soot emissions needed to meet climate change goals 2Aggressive action to reduce soot emissions needed to meet climate change goals 3New diagnostic test for bladder cancer 2
... Detection of the yolk protein Vtg in ... simple and sensitive biomarker for endocrine disrupting chemicals ... Vtg has become an accepted screening test for ... Vtg (rainbow trout) EIA kit is a double-antibody ...
... Laboratory (RTL) can provide you with ... ,,Microbial method development and validation ,Performance ... conditions of your GMP manufacturing environment ... offer a full spectrum of microbiological ...
... amino acid synthetic peptide whose sequence is from rat SCAMP 5. ... C - N(217) - Q - P - Q - ... - P - N - Y - T - Y - ... neutralization and control experiments with the polyclonal antibody that reacts with ...
... (gram quantities of IgY) , After we receive ... we segregate the appropriate number of chickens and ... eggs are collected (usually over a period of ... involves a total of four injections into the ...
Biology Products: